Recombinant adeno-associated viral (AAV)-mediated therapeutic gene transfer to dorsal root ganglia (DRG) is an effective and safe tool for treating chronic pain. However, AAV with various constitutively active promoters leads to transgene expression predominantly to neurons, while glial cells are refractory to AAV transduction in the peripheral nervous system. The present study evaluated whether in vivo satellite glial cell (SGC) transduction in the DRG can be enhanced by the SGC-specific GFAP promoter and by using shH10 and shH19, which are engineered capsid variants with M€ uller glia-prone transduction.
chemokine/cytokine release, which induces microglia activation (Liu & Yuan, 2014; McMahon & Malcangio, 2009; Milligan & Watkins, 2009; Watkins & Maier, 2003) . Genetic manipulation of SGC-specific molecules such as connexin 43 (Cx43) , glutamine synthase (GS) (Jasmin, Vit, Bhargava, & Ohara, 2010) , ATP-sensitive inward rectifier potassium channel 10 (K ir 4.1) (Vit, Ohara, Bhargava, Kelley, & Jasmin, 2008) , excitatory amino acid transporter 1 (EAAT1) (Jasmin et al., 2010) , purinergic ionotropic P2X7 receptor (P2X7R) (Chen et al., 2008) , and GFAP (Kim et al., 2009) , can substantially alter sensory responses in normal and nerve-injured rodents. Thus, therapeutic gene modulation specifically targeting the SGC population in dorsal root ganglia (DRG) could offer new opportunities for chronic pain treatment (Gao & Ji, 2010; Jasmin et al., 2010; McMahon & Malcangio, 2009 ).
Gene therapy has demonstrated a potential for novel treatments for chronic pain. In preclinical studies, gene delivery by use of adenoassociated viral (AAV) has been established as an efficient tool for gene transfer into postmitotic peripheral sensory neurons and for long-term control of neuropathic pain with minimal toxicity (Asokan, Schaffer, & Samulski, 2012; Beutler, 2010; Beutler & Reinhardt, 2009; Mason et al., 2010; Yu et al., 2013) . The capsid protein and the promoter are major determinants of AAV tropism to different cell types. The natural tropism of AAV vectors based on the widely used AAV2 genome with constitutively active promoters and pseudotyped with various serotype capsids leads predominantly to neuronal transduction. Although variable, a low level of nonselective SGC transduction in vivo after intraganglionic delivery has been reported, and the use of AAV to transduce SGCs has generally resulted in limited success in adult animals (Asokan et al., 2012; Beutler, 2010; Beutler & Reinhardt, 2009; Mason et al., 2010; Yu et al., 2013) . This view has been challenged in the central nervous system by showing that use of a GFAP promoter increases the astrocyte transduction of AAV-mediated transgene expression (von Jonquieres et al., 2013) . However, whether GFAP promoter determines glial cell transduction in DRG has not been reported. Capsid protein is another important determinant for AAV tropism. AAVshH10 (an AAV6 capsid variant) and AAVshH19 (an AAV2 capsid variant) are recently engineered novel AAV capsids that provide efficient M€ uller glia-permissive gene expression (Dalkara et al., 2011; Koerber et al., 2009; Zolotukhin et al., 2013) . It is not clear, however, whether these AAV capsid mutants can be adopted for gene transfer to ganglionic SGCs.
The purpose of this study was to evaluate whether cell specificity for the SGC transduction in DRG could be enhanced using AAVshH10 and AAVshH19 capsids, and transgene-driven by SGC-specific GFAP promoter. Our work establishes that GFAP promoter is effective in providing SGC-selective transgene expression following intraganglionic AAV delivery in adult rats, and this strategy should prove useful for the development of gene expression systems targeting SGC signaling for chronic pain. Guidelines for the Care and Use of Laboratory Animals. Animals were housed individually in a room maintained at constant temperature (22 8C 6 0.5 8C) and relative humidity (60% 6 15%) with an alternating 12-hr light-dark cycle. Animals had access to water and food ad libitum throughout the experiment, and all efforts were made to minimize suffering.
| AAV production
AAV vectors were produced and purified in our laboratory by previously described methods (Yu et al., 2013 ). This included AAV particle purification by OptiPrep ultracentrifugation and concentration by use of Centricon Plus-20 (Regenerated Cellulose 100,000 MWCO, Millipore, Billerica, MA). AAV titer was determined by PicoGreen (Life Technologies, Carlsbad, CA) assay, and final aliquots were kept in 1 3 phosphate buffered saline (PBS) containing 5% sorbitol (SigmaAldrich, St. Louis, MO) and stored at 280 8C. Plasmids of capsid AAV6 and two glia-prone capsid variants (AAVshH10 and AAVshH19) were used as reported in previous publications Yu et al., 2013) . pAAV-GFAP-EGFP shuttle plasmid (containing a compact GFAP promoter, 694bp gfaABC1D) was purchased from Addgene (plasmid#: 50473, Cambridge, MA). The gfaABC1D promoter is suitable for packaging into AAV vectors and has been reported to have essentially the same expression pattern as the full GFAP promoter (Lee, Messing, Su, & Brenner, 2008) . Five different AAVs were prepared: AAV2/6 expressing EGFP driven by the CMV or GFAP promoter (subsequently referred to as AAV6-CMV-EGFP and AAV6-GFAP-EGFP), and two M€ uller glia-prone capsid-mutant vectors with the same AAV expressing EGFP by CMV promoter but packaged with capsids shH10 and shH19 and by GFAP promoter with capsid shH10 (subsequently referred to as AAVshH10-CMV-EGFP, AAVshH19-CMV-EGFP, and AAVshH10-GFAP-EGFP). The titers (GC/ml) of AAV6-CMV-EGFP, AAV6-GFAP-EGFP, AAVshH10-CMV-EGFP, AAVshH19-CMV-EGFP, , respectively. The same lot of viral preparation was used for all in vivo experiments. Vectors were evaluated for purity by sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) electrophoresis followed by silver stain using a Pierce silver stain kit (Fisher Scientific, Rockford, IL) according to manufacturer's protocol (Supporting Figure 1 ). An AAV6-CMV-mCherry with a titer of 1.21 3 10 13 GC/ml was purchased from Vigene Biosciences (Rockville, MD).
| Injection of AAV vectors into the DRG
AAV vectors were microinjected into the right lumbar (L) 4 and L5 DRG of isoflurane-anesthetized rats, performed through a micropipette using previously described techniques . Briefly, the surgically exposed intervertebral foramen was minimally enlarged by 
| Characterization of neurotropism of intraganglionic AAV-mediated transgene expression
Five weeks after injection, animals were terminally anesthetized. DRG were dissected, postfixed in 4% PFA, and processed for paraffin embedding and sectioning. Double immunolabeling histochemistry (IHC) was performed to characterize cellular specificity and distribution of target molecules in sections, as described in a previous publication . In brief, 5-lm-thick sections were deparaffinized and rehydrated through graded alcohol. Sections were immunolabeled with the selected primary antibodies (Table 1 ). All antibodies were diluted in 1 3 PBS containing 0.05% Triton X-100 and 3% bovine serum albumin.
Normal immunoglobulin G (from the same species as the first antibody)
was replaced for the first antibody as the negative controls (Table 1) by subtracting 0.5 from this ratio. In random staining, the ICQ approximates 0. In segregated staining, ICQ is less than 0; while for dependent staining, ICQ is greater than 0.
Quantification of transgene expression in neurons or SGCs was determined as reported previously (Puljak, Kojundzic, Hogan, & Sapunar, 2009; Yu et al., 2013) . Immunostaining of Tubb3 (a pan-neuronal marker) and GFAP or GS (SGC markers) was used to distinguish neurons and SGCs, respectively. Neurons and SGCs can also be distinguished in Hoechst counterstain; neuronal nuclei are larger and less intensively stained compared with SGC nuclei (Wang et al., 2016) . Neurons that were surrounded by EGFP 1 SGC rings colabeled with GFAP or GS by more than 50% of their circumference were counted and expressed as a percentage of neurons with EGFP 1 SGC rings per total neurons present in the fields (Nascimento, Castro-Lopes, & Moreira Neto, 2014) . EGFP 1 neurons were defined as the neurons with a fluorescence intensity greater than the average background fluorescence plus 2 standard deviations of neurons in a section from a naïve animal (no vector injection) under identical acquisition parameters (Yu et al., 2013 ).
| Western blotting
Lysates of HEK293T cells and DRG tissues were extracted using 1 3 RIPA buffer (20 mm Tris-HCl pH 7.4, 150 mm NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, with 0.1% Triton X100 and protease inhibitor cocktail). Protein concentration determined by using the BCA kit (Pierce, Rockford, IL). Western blotting of cell lysates or tissue homogenates (20-lg protein) was preceded by SDS-PAGE gel electrophoresis, transferred onto nitrocellulose, and probed with a polyclonal rabbit anti-GFP antibody (1:1,000; Cell Signaling, Danvers, MA), rabbit anti-mCherry antibody (1:500, Life Technologies), or anti-GFAP (1:1,000, Dako, Carpinteria, CA). Immunoreactive proteins were detected by enhanced chemiluminescence (Pierce, Rockford, IL) after incubation with HRP-conjugated second antibodies (1:2,000, SCB) and exposed to photographic film. GAPDH was used as a loading control. Ratios of the band density of GFAP protein to the GAPDH were calculated, and the percent changes of GFAP in the sham and the injected DRG samples were normalized against the average of naïve samples Wang et al., 2016. 
| Statistics
All statistical analysis was performed using Prism (GraphPad Software, La Jolla, CA (Li et al., 2004) .
| R ESU L TS

| GFAP promoter restricts AAV6-mediated transgene expression to SGCs
We initially tested the properties of AAV with the GFAP promoter, compared with the CMV promoter, in expressing a transgene in SGCs after delivery to the DRG. Both CMV and GFAP promoters driving the EGFP gene were packaged into AAV6 vectors with a single-stranded AAV2 genome. Animals were euthanized 5 weeks after administration, DRGs were sectioned, and cell specificity of EGFP expression was analyzed by immunofluorescence using GFP antibodies for which the specificity to detect EGFP expression in sections was verified (cf. Supporting Figures 2a and 3 ). Similar to our previous reports (Yu et al., 2013; , intraganglionic injection of Examining only the EGFP fluorescence immediately surrounding the SGC nucleus avoids the ambiguities of counting areas where cytoplasm is minimal, which makes transduction hard to confirm by fluorescence, and which makes SGC enumeration impossible because their processes overlap. Among these clearly identified SGCs, transduction rates by AAV6-GFAP-EGFP were 70% 6 8% (n 5 4 DRG sections, total 598 SGCs) using GFAP for identification and 72% 6 6% using GS for identification (n 5 4 DRG sections, total 1,107 SGCs; Supporting Figure 4 ).
Additional confirmation of SGC localization of transgene expression transferred by AAV6-GFAP-EGFP was obtained through costaining of EGFP with other glial cell markers for SGCs including
Vimentin, GS, K ir 4.1, EAAT1, and Hmgcs1, and with SGC/Schwann cell co-positive marker S100, as well as with Iba1 for microglial cells (Wang et al., 2016) . Results showed (compared with the negative IHC controls shown in Supporting Figure 2b ) that GFAP promoter-driven EGFP expression was colabeled with each of the SGC markers but colocalization was not evident with Iba1 ( Figure 2a) . We also used the ICA method to quantitatively evaluate the coexpression of EGFP with We also prepared AAVshH10-GFAP-EGFP and injected 2 3 10 10 GC particles into L4/L5 DRG (n 5 4 rats), after which in vivo transduction was analyzed 5 weeks later by IHC. This showed that this construct also induced efficient transgene expression selectively to SGCs (Figure 6 ), similar to AAV6-GFAP-EGFP.
Comparison of the transduction properties of all five vectors (Figure 7) shows that both AAV6-GFAP-EGFP and AAVshH10-GFAP-EGFP produce efficient SGC-selective transgene expression, whereas AAV6-CMV-EGFP, AAVshH10-CMV-EGFP, and AAVshH19-CMV-EGFP fail to transduce SGCs (F 4,20 5 33.5, p < .001, Figure 7a ). In contrast, AAV6-GFAP-EGFP and AAVshH10-GFAP-EGFP produce limited neuronal transduction, while AAVs using CMV promoters (AAV6-, shH10-, shH19-CMV-EGFP) produce robust neuronal transduction (F 4,34 5 18.58, p < .001, Figure 7b ).
| Effective delivery of two transgenes to SGCs and neurons separately by dual AAV vectors
This study was designed to examine the strategy of using two simultaneously applied AAV vectors to separately express distinct transgenes showed 40% 6 8% EGFP 1 SGC rings and 34% 6 11% mCherry 1 neuron soma. These results indicate that this dual AAV strategy is successful in driving selective expression in DRG neurons versus SGCs using a GFAP promoter to express one transgene in SGCs while using CMV promoter to target another transgene expression only in neurons.
| D I SCUSSION
SGCs represent a predominant glial cell type in the DRG, host a complex network of signaling pathways, and are recognized as an important sensory component and mediators in pain sensation (Pannese, 2010; Wang et al., 2016) . Development of an SGC-permissive AAV vector would be valuable for expanding the utility of AAV in modeling and treating chronic pain. In vitro studies show efficient glial cell transduction for all serotype AAV vectors (Howard, Powers, Wang, & Harvey, 2008) , and a number of AAV serotypes have shown variable glial tropism in vivo in various neural tissues by different routes of application (Aschauer, Kreuz, & Rumpel, 2013; Koerber et al., 2009; Mason et al., 2010; Petrosyan et al., 2014; Samaranch et al., 2013; Wollmann, Tattersall, & van den Pol, 2005; Yu et al., 2013) . However, the results have not translated into reliable, specific, and widespread transduction of SGCs in the DRG.
In this study, we evaluated the specificity and efficiency of targeting SGCs relative to primary sensory neurons, using AAV vectors incorporating either a GFAP promoter or a constitutively active CMV
promoter. The data demonstrate that the AAV with a GFAP promoter was capable of discriminating for SGC transduction. Our data show that transgene expression was highly selective for SGCs and virtually after nerve injury might be capable of targeting and controlling the highly proliferated glial cell population that follows nerve injury in neuropathic pain (Ji, Berta, & Nedergaard, 2013) .
We also examined cell specificity of AAVs packaged by use of the recently engineered "M€ uller glia-prone" capsid AAVshH10, an AAV6 variant that is highly homologous to its parent AAV6 with only four different capsid residues, and AAVshH19, an AAV2 variant that is a chimera composed of capsid regions from several serotypes swapped into AAV2. Previous reports show substantially increased transduction of M€ uller glial cells by these capsid variants when applied by intravitreal route compared with AAV6 and AAV2 controls (Vandenberghe & Auricchio, 2012) . Our results show that a single intraganglionic injection of AAVshH10 or AAVshH19 carrying a CMV-EGFP cassette induced highly efficient, selective transduction of sensory neurons, but no significant enhancement in transduction of SGCs. This indicates that although the divergent capsid residues in AAVshH10 and AAVshH19 may act in concert to improve glia transduction in the visual system or brain glioma (Byrne et al., 2013; Klimczak et al., 2009; Koerber et al., 2009; Pellissier et al., 2014; Vacca et al., 2016) , this shift in tropism does not occur when applied in DRG. Nonetheless, the capsid variants of shH10 and shH19 may be considered for use as viable alternatives to AAV6 and AAV2 for efficient neuronal transduction in DRG.
A unique characteristic of DRG structure is that SGCs tightly ensheathe the somata of primary sensory neurons to form discrete anatomical and functional sensory units (Pannese, 2010; Wang et al., 2016) . Bidirectional neuron-SGC communication plays an essential role in regulating afferent signaling (Huang, Gu, & Chen, 2013; Kim et al., 2016; Rozanski, Nath, Adams, & Stanley, 2013; Zhang et al., 2015) . Understanding the complex neuron-SGC communication in normal and injured DRG relies on the availability of experimental systems to separately target primary sensory neurons and SGCs in vivo. Therefore, AAV vectors with high, equivalent, and reliable tropism for both primary sensory neurons and SGCs will be valuable but are yet to be identified. We have demonstrated that a dual AAV strategy using two vectors, one with GFAP promoter and the other with CMV promoter, In summary, this report, together with our prior studies (Yu et al., 2013; Yu et al., 2016) , demonstrates that GFAP promoter, but not capsid divergence, offers an efficient pathway for selective gene expression in SGCs following intraganglionic AAV delivery in adult rats. A dual AAV system, one with GFAP promoter and the other with CMV promoter, can efficiently express transgenes selectively in neurons versus SGCs. Future research may develop the therapeutic potential of GFAP promoter AAV in targeting SGC signaling for chronic pain.
